Volume 2.11 | Mar 22

Hematopoiesis News 2.11, March 22, 2011.
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
 
TOP STORY
HIV-1 Utilizes the CXCR4 Chemokine Receptor to Infect Multipotent Hematopoietic Stem and Progenitor Cells
Scientists provide direct evidence that HIV targets long-lived hematopoietic stem cells (HSCs) and show that infected HSCs yield stable, multilineage engraftment in a xenograft model. [Cell Host Microbe]

STEMvision_645x110_v01a.jpg
SPECIAL FEATURE

Webinar: ALDHbr Cells and Regenerative Medicine
Aldehyde Dehydrogenase bright (ALDHbr) cells have been used in preclinical models and human clinical trials in applications such as critical limb ischemia, ischemic stroke, acute liver failure and ischemic heart failure.1 Learn more about how ALDHbr cells could be used in regenerative medicine by registering today for an exclusive webinar presented by Dr. Andrew E. Balber of Cicada Biopharmaceutical Consulting.

Join us on April 7 at: 10AM EST (ideal for Europe) | 2PM EST (ideal for Americas) | 8PM EST (ideal for Asia-Pacific)

1 Reviewed in Balber AE. Stem Cells (in press). DOI: 10.1002/stem.613.
Dr. Balber holds equity in and is a consultant to Aldagen, Inc., a company that is developing research, diagnostic, and therapeutic products based on detecting and isolating ALDHbr cells.



social_default_facebook_icon.jpg “Like” Cell Therapy News on Facebook for a chance to win an Amazon gift card!

social_default_twitter_icon.jpg Follow us on Twitter! @Hema_News

Interested in recruiting talented individuals? Post your career opportunities in Hematopoiesis News at no cost. Contact us at
[email protected]
SCIENCE NEWS
Leukemia Patients Get Unnecessarily High Chemotherapy Dose
For decades now, patients with the most common type of leukemia (acute myeloid leukemia) have been receiving a chemotherapy dose that is ten times higher than necessary. [Press release from Erasmus Medical Center discussing online prepublication in The New England Journal of Medicine]

MethoCultExpressVideo_v02_645x110.jpg
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)
LABORATORY RESEARCH

An Anticlastogenic Function for the Polycomb Group Gene Bmi1
Researchers show that transformed human cell lines as well as primitive hematopoietic cells exhibit a high frequency of spontaneous chromosome breaks upon BMI1 depletion and are hypersensitive to genotoxic agents. [Proc Natl Acad Sci U S A]

CD41 Is Developmentally Regulated and Differentially Expressed on Mouse Hematopoietic Stem Cells
Differential and temporal expression of CD41 by hematopoietic stem cells in the distinct hematopoietic territories suggests a developmental/dynamic regulation of this marker throughout development. [Blood]

CD146 Expression on Primary Non-Hematopoietic Bone Marrow Stem Cells Correlates to In Situ Localization
Findings show that the expression of CD146 differentiates between perivascular versus endosteal localization of non-hematopoietic bone marrow stem cell populations, which has apparent implications for the study of the hematopoietic environment. [Blood]

Oxygen-Regulated Expression of the Erythropoietin Gene in a Human Renal Cell Line REPC
Here scientists present the human kidney cell line REPC (for renal erythropoietin (EPO) producing cells), established from an explanted human kidney which shows EPO gene expression and release of EPO protein in an oxygen-dependent manner. [Blood]

Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors
The purpose of this study was to determine whether mTORC2 and RI-mTORC1 complexes are present in AML cells and to examine the effects of dual mTORC2/mTORC1 inhibition on primitive AML leukemic progenitors. [Clin Cancer Res]

Phosphorylation of p27Kip1 by JAK2 Directly Links Cytokine Receptor Signaling to Cell Cycle Control
In this study, researchers describe the identification of the cyclin-dependent kinase inhibitor p27Kip1 as a novel janus kinase 2 (JAK2) substrate. [Oncogene]

Bcl-XL Is a Dominant Antiapoptotic Protein Which Inhibits Homoharringtonine-Induced Apoptosis in Leukemia Cells
To investigate its mechanism of action, cell growth inhibition and cytotoxicity of homoharringtonine were investigated in three acute myeloid leukemia cell lines, HL-60, NB4, and U937, and in three chronic myeloid leukemia cell lines, K562, KU812, and KCL22. [Mol Pharmacol]

FLT3-Regulated Antigens as Targets for Leukemia-Reactive Cytotoxic T Lymphocytes
Investigators analyzed the regulation of leukemia-associated antigen in FMS-like tyrosine kinase 3 (FLT3)-wild-type and FLT3-Internal tandem duplications+ myeloid cells to identify potential targets for antigen-specific immunotherapy for acute myeloid leukemia patients. [Blood Cancer J]

CLINICAL RESEARCH

Cytarabine Dose for Acute Myeloid Leukemia
Scientists compared two induction regimens in patients 18 to 60 years of age (median, 49) who had newly diagnosed acute myeloid leukemia. [N Engl J Med]

Autologous Transplantation Gives Encouraging Results for Young Adults with Favorable-Risk Acute Myeloid Leukemia but Is Not Improved with Gemtuzumab Ozogamicin
Researchers report the results of a prospective, randomized Phase III trial evaluating the use of gemtuzumab ozogamicin in an intensive consolidation approach in 657 patients, ages 17 to 60 years. [Blood]

A Phase I/II Study of Imatinib Plus Reinduction Therapy for c-Kit-Positive Relapsed/Refractory Acute Myeloid Leukemia: Inhibition of Akt Activation Correlates with Complete Response
This Phase I/II study evaluated imatinib as a c-kit inhibitor combined with mitoxantrone, etoposide and cytarabine therapy for patients with primary refractory or relapsed c-kit+ acute myeloid leukemia. [Leukemia]
INDUSTRY NEWS
Funding Boost Brings Industrially-Generated Blood Closer to Reality
The constant search for enough donated blood to meet demand could become a thing of the past, thanks to research into the development of industrially-generated blood funded by the Scottish Funding Council. [Scottish Funding Council Press Release]

Cellectis and the Etablissement Français du Sang Launch StemRed, a Program to Produce Red Blood Cells from Stem Cells
Cellectis and Etablissement Français du Sang announce that StemRed, an ambitious collaborative program to produce red blood cells from induced pluripotent stem cells has started. [Cellectis Press Release]

Fortis Healthcare Ties Up with TotipotentRX to Set Up Stem Cell Therapy Centers
Fortis Healthcare (India) Ltd. and TotipotentRX Cell Therapy Pvt. Ltd. announced a collaboration to set up centers of excellence offering cellular therapies and stem cell clinical trials, across select Fortis hospitals. [Fortis Healthcare Ltd. Press Release]

Second Phase III Study of Novartis JAK Inhibitor INC424 Meets Primary Endpoint in Patients with Myelofibrosis
Novartis announced that a pivotal Phase III trial of the investigational Janus kinase (JAK) inhibitor INC424 (ruxolitinib) has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis. [Novartis Press Release]

U.K. – U.S. Stem Cell Collaboration Announced
A Memorandum of Understanding between the U.K. Stem Cell Bank and the University of Massachusetts Human Stem Cell Bank and Registry was signed. [U.K. Stem Cell Bank Press Release]
POLICY NEWS
Medicare Proposes No Changes for Anemia Drugs
Medicare officials do not plan at this time to change payment terms for anemia drugs used in kidney patients who are undergoing dialysis. [Medicare, United States]

Myeloma U.K. Writes to Iain Duncan Smith MP About Proposed Overhaul of the Benefits System
Myeloma U.K. has joined 30 other cancer charities in raising concerns about the impact for cancer patients of the Government’s proposed changes to the benefits system. [Department for Work and Pensions, United Kingdom]

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS
NEW Targeted Antibodies for Cancer 2011
August 10-11, 2011 
London, United Kingdom

NEW International Conference and Exhibition on Cancer Science & Therapy
August 15-17, 2011 
Las Vegas, United States

Visit
our events page to see a complete list of events in the hematopoietic community.
JOB OPPORTUNITIES
Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Supervisor Cell Therapy Laboratory – Cord Blood Bank (The University of Texas MD Anderson Cancer Center)

Postdoctoral Research Scientist in Bone and Hematopoiesis (New York University)

Research Associate (University of Massachusetts Medical School)

Post-Doctoral Research Fellows – Transcriptional Control in Hematopoietic Stem Cells and Leukemia (Institut de Recherches Cliniques de Montréal) 

Research Technologist – Pharmaceutical Sciences (St. Jude Children’s Research Hospital)

Associate or Assistant Researcher (University of Wisconsin-Madison)

Investigator (The Children’s Hospital of Philadelphia and the University of Pennsylvania’s School of Medicine Academic)

Postdoctoral Fellow or Research Associate (City University of New York)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.

Visit
here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us